https://www.selleckchem.com/pr....oducts/alw-ii-41-27.
There was no difference in the incidence of adverse events between the zonisamide and placebo groups except for decreased appetite, which had an increased frequency in the zonisamide 50 mg group compared with placebo. Our findings indicate that zonisamide improved parkinsonism with DLB without deterioration of cognitive function and or worsening behavioral and psychological symptoms of dementia. Our findings indicate that zonisamide improved parkinsonism with DLB without deterioration of cognitive function and or worsening behavior
Like
Comment
Share
